Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14889644 | 0.94 | — | — | |
| SCHEMBL630218 | 0.79 | CYP2C19 (0.39) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL17152527 | 0.78 | CYP2C19 (0.38) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL15059607 | 0.77 | CYP2C19 (0.35) | CYP2C19 | |
| SCHEMBL6136974 | 0.76 | CYP2C19 (0.43) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL11765654 | 0.76 | CYP2C19 (0.36) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL7038806 | 0.75 | CYP2C19 (0.34) | CYP2C19ALDH1A1TSHR | |
| SCHEMBL1516357 | 0.73 | CYP2C19 (0.39) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL6802203 | 0.73 | CYP2C19 (0.34) | CYP2C19ALDH1A1 | |
| SCHEMBL1231768 | 0.72 | CYP2C19 (0.40) | CYP2C19USP2ALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-2897939-B1 | BENZOIMIDAZOLE-CARBOXYLIC ACID AMIDE DERIVATIVES FOR TREATING METABOLIC OR CARDIOVASCULAR DISEASES | SANOFI SA (FR) | 2017-02-01 | — | — | EP | disclosed |
| US-9156796-B2 | Benzoimidazole-carboxylic acid amide derivatives as APJ receptor modulators | SANOFI (FR) | 2015-10-13 | — | — | US | disclosed |
| EP-2897939-A1 | BENZOIMIDAZOLE-CARBOXYLIC ACID AMIDE DERIVATIVES AS APJ RECEPTOR MODULATORS | SANOFI (FR) | 2015-07-29 | — | — | EP | disclosed |
| WO-2014044738-A1 | BENZOIMIDAZOLE-CARBOXYLIC ACID AMIDE DERIVATIVES AS APJ RECEPTOR MODULATORS | SANOFI (FR) | 2014-03-27 | — | — | WO | disclosed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | CYP2C19 1755/4885USP2 4508/4885ALDH1A1 3589/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | CYP2C19 1755/4885USP2 4508/4885ALDH1A1 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.